Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $168 and keeps an Equal Weight rating on the shares. The company reported a solid quarter and guidance, which implies recent utilization and revenue trends remain stable, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports Strong Growth and Future Confidence
- Morning Movers: UPS and Cigna plunge double digits following Q4 results
- Quest Diagnostics increases quarterly dividend 6.7% to 80c per share
- Quest Diagnostics reports Q4 adjusted EPS $2.23, consensus $2.18
- Quest Diagnostics sees FY25 adjusted EPS $9.55-$9.80, consensus $9.72